An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE

The Journal of pharmacology and experimental therapeutics1 Jun 1991Cited by 101 (Europe PMC)

PMID1646331DOI10.1016/s0022-3565(25)24703-6PepBankPUB-01646331

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In CNS cell cultures, a hybrid VIP-neurotensin antagonist displaced 80 to 90% of [125I]VIP binding.
In plain wordsIn cells, a lab-made VIP blocker pushed 80 to 90% of labelled VIP off its binding sites. This tests the blocker.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseDisplacement of [125I]VIP binding by the hybrid antagonist
Study
n: not reported in source
Cell cultures from cerebral cortex, hippocampus or spinal cord
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Measurements
VIP binding displaced
80 to 90%
cerebral cortex, hippocampus or spinal cord cultures
Source sentences
Summary
The hybrid antagonist displaced 80 to 90% of [125I]VIP binding to cell cultures from cerebral cortex, hippocampus or spinal cord.
1 context sentence(design, population, supporting numbers)
Summary · context
A vasoactive intestinal peptide (VIP) antagonist was synthesized and used to investigate the interactions of VIP with its receptors present in the central nervous system (CNS).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0164633101
02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In cortical astrocytes, the hybrid VIP antagonist had a Ki of 45 pM at one binding site and 74 nM at the other.
In plain wordsIn cells, a lab-made VIP blocker bound two different sites on brain support cells, one very tightly and one more weakly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableAntagonist affinity (Ki) at two binding sites in cortical astrocytes
Study
n: not reported in source
Cell cultures from cerebral cortex, hippocampus or spinal cord
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Measurements
Ki
45 pM
cortical astrocytes, high-affinity site
Ki
74 nM
cortical astrocytes, low-affinity site
Source sentences
Summary
In the case of cortical astrocytes, the antagonist had a Ki of 45 pM at one site and a Ki of 74 nM at the other.
1 context sentence(design, population, supporting numbers)
Summary · context
A vasoactive intestinal peptide (VIP) antagonist was synthesized and used to investigate the interactions of VIP with its receptors present in the central nervous system (CNS).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0164633102
03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
At the lower affinity binding site, the hybrid antagonist was about 10-fold more potent than VIP in displacing radiolabeled VIP.
In plain wordsIn cells, the lab-made blocker was about 10 times stronger than VIP at displacing labelled VIP from the weaker binding site.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseAntagonist potency versus VIP at the lower affinity site
Study
n: not reported in source
Cell cultures from cerebral cortex, hippocampus or spinal cord
Comparator
VIP
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Measurements
relative potency versus VIP
10 fold
lower affinity binding site
Source sentences
Summary
At the lower affinity binding site, the antagonist was about 10-fold more potent than VIP in displacing radiolabeled VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
A vasoactive intestinal peptide (VIP) antagonist was synthesized and used to investigate the interactions of VIP with its receptors present in the central nervous system (CNS).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0164633103
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In cortical glia cultures, the hybrid antagonist decreased VIP-stimulated cAMP accumulation (EC50, 59 nM).
In plain wordsIn cells, the lab-made blocker lowered the cAMP rise caused by VIP in brain support cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasecAMP accumulation in VIP-stimulated cortical glia
Study
n: not reported in source
Cell cultures from cerebral cortex, hippocampus or spinal cord
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Measurements
EC50
59 nM
VIP-stimulated cortical glia cultures
Source sentences
Summary
The accumulation of cyclic AMP (cAMP) in VIP-stimulated cortical glia cultures was decreased by the new antagonist (EC50, 59 nM).
1 context sentence(design, population, supporting numbers)
Summary · context
A vasoactive intestinal peptide (VIP) antagonist was synthesized and used to investigate the interactions of VIP with its receptors present in the central nervous system (CNS).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0164633104
05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Efficacy outcome
In dissociated spinal cord cultures, 1 nM hybrid antagonist reduced neuronal cell counts by 42% compared with controls (EC50 about 30 pM).
In plain wordsIn cells, adding a lab-made VIP blocker cut the number of spinal cord neurons by 42% compared with controls.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseNeuronal cell counts in spinal cord cultures
Study
n: not reported in source
Cell cultures from cerebral cortex, hippocampus or spinal cord
Comparator
Controls
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
neuronal cell count reduction
42%
1 nM antagonist
EC50
≈ 30 pM
spinal cord cultures
Source sentences
Summary
Finally, the addition of 1 nM hybrid antagonist to dissociated spinal cord cultures resulted in a 42% reduction in neuronal cell counts as compared with controls, and the EC50 of this effect was about 30 pM, which corresponded closely to the Ki of antagonist displacement of [125I]VIP binding at the high-affinity site.
1 context sentence(design, population, supporting numbers)
Summary · context
A vasoactive intestinal peptide (VIP) antagonist was synthesized and used to investigate the interactions of VIP with its receptors present in the central nervous system (CNS).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0164633105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.